UsAgainstAlzheimer’s Applauds FDA Approval of Leqembi for Treatment of Early-Stage Alzheimer’s Washington, DC, July 06, 2023 (GLOBE NEWSWIRE) -- Patient advocacy organization UsAgainstAlzheimer’s today hailed the first-of-its-kind traditional approval by the Food and Drug Administration (FDA)...

Global Alzheimer’s Platform Foundation (GAP) President Blasts CMS’ “Unprecedented and Pernicious” Discrimination Against People with Alzheimer’s Disease Washington, D.C., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Statement by Global Alzheimer’s Platform Foundation® President John Dwyer: “Once again, the Centers for Medicare and Medicaid Services (CMS) has...

Global Alzheimer’s Platform Foundation Statement on FDA Accelerated Approval of Lecanemab Washington, D.C., Jan. 06, 2023 (GLOBE NEWSWIRE) -- "We applaud the Food and Drug Administration (FDA)’s decision to grant accelerated approval to lecanemab, a treatment that offers millions of...

Sen. Collins, Rep. Eshoo Decry Medicare Coverage Rejection of Alzheimer’s Drugs Washington, D.C., Oct. 18, 2022 (GLOBE NEWSWIRE) -- During UsAgainstAlzheimer’s 2022 National Summit, members of Congress, scientists, and other leaders spoke out against the Centers for Medicare...